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Abstract
Objective The objectives of the present study were to investigate (1) whether trinary visual interpretation of amyloid positron 
emission tomography (PET) imaging (negative/equivocal/positive) reflects quantitative amyloid measurements and the time 
course of 11C-Pittsburgh compound B (PiB) amyloid accumulation, and (2) whether visually equivocal scans represent an 
early stage of the Alzheimer’s disease (AD) continuum in terms of an intermediate state of quantitative amyloid measure-
ments and the changes in amyloid accumulation over time.
Methods From the National Bioscience Database Center Human Database of the Japanese Alzheimer’s Disease Neuroim-
aging Initiative, we selected 133 individuals for this study including 33 with Alzheimer’s disease dementia (ADD), 52 with 
late mild cognitive impairment (LMCI), and 48 cognitively normal (CN) subjects who underwent clinical assessment, PiB 
PET, and structural magnetic resonance imaging (MRI) with 2 or 3-years of follow-up. Sixty-eight of the 133 individuals 
underwent cerebrospinal fluid amyloid-β1-42 (CSF-Ab42) analysis at baseline. The standard uptake value ratio (SUVR) of 
PiB PET was calculated with a method using MRI at each visit. The cross-sectional values, longitudinal changes in SUVR, 
and baseline CSF-Ab42 were compared among groups, which were categorized based on trinary visual reads of amyloid 
PET (negative/equivocal/positive).
Results From the trinary visual interpretation of the PiB PET images, 55 subjects were negative, 8 were equivocal, and 70 
were positive. Negative interpretation was most frequent in the CN group (70.8/10.4/18.8%: negative/equivocal/positive), 
and positive was most frequent in the LMCI group (34.6/1.9/63.5%) and in the ADD group (9.1/6.1/84.8%). The baseline 
SUVRs were 1.08 ± 0.06 in the negative group, 1.23 ± 0.15 in the equivocal group, and 1.86 ± 0.31 in the positive group 
(F = 174.9, p < 0.001). The baseline CSF-Ab42 level was 463 ± 112 pg/mL in the negative group, 383 ± 125 pg/mL in the 
equivocal group, and 264 ± 69 pg/mL in the positive group (F = 37, p < 0.001). Over the 3-year follow-up, annual changes 
in SUVR were − 0.00 ± 0.02 in the negative group, 0.02 ± 0.02 in the equivocal group, and 0.04 ± 0.07 in the positive group 
(F = 8.4, p < 0.001).
Conclusions Trinary visual interpretation (negative/equivocal/positive) of amyloid PET imaging reflects quantitative amyloid 
measurements evaluated with PET and the CSF amyloid test as well as the amyloid accumulation over time evaluated with 
Data used in preparation of this article were obtained from the 
Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) 
database deposited in the National Bioscience Database Center 
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PET over 3 years. Subjects in the early stage of the AD continuum could be identified with an equivocal scan, because they 
showed intermediate quantitative amyloid PET, CSF measurements, and the amyloid accumulation over time.
Keywords Alzheimer’s disease · Amyloid · 11C-PiB PET · Visual interpretation · Longitudinal
Introduction
Alzheimer’s disease (AD) is the most common cause of 
dementia. Amyloid accumulation is predictive of a high prob-
ability of AD and is thought to begin before the appearance of 
clinical symptoms [1]. Amyloid positron emission tomography 
(PET) imaging using 11C-Pittsburgh compound B (PiB) has 
enabled visual and quantitative evaluation of cortical amyloid 
deposition in vivo [2, 3]. Time-course changes of amyloid dep-
osition have been investigated using longitudinal semiquantita-
tive values such as the standardized uptake value ratio (SUVR) 
of amyloid PET data. Groups with high accumulation and low 
accumulation of amyloid PET, which were divided according 
to cutoff values obtained by various methods, have demon-
strated increasing and non-increasing deposition of amyloid, 
respectively [4–8]. Visual inspection may detect deposition 
of amyloid plaques earlier than semiquantitative methods [9]. 
However, there has been no research that stratified amyloid 
accumulation by visual interpretation in longitudinal analyses. 
In recent years, research interest has moved to detection of the 
earliest accumulation of amyloid and how it changes over time, 
as well as how it relates to neurodegeneration and the decline 
in cognitive function, since accurate understanding of the rela-
tionship between clinical status and the extent of progression 
of amyloid pathology is necessary to develop amyloid-targeted 
treatment plans.
In this study, the longitudinal changes of PiB PET in 
the Japanese Alzheimer’s Disease Neuroimaging Initiative 
(J-ADNI), a multicenter, prospective, observational study 
of Japanese subjects, were analyzed. In J-ADNI, visual 
interpretation of amyloid PET was performed based on tri-
nary reading (negative, equivocal, or positive) according to 
strict reading criteria and a consensus process [10], which 
are different from the common visual interpretation of amy-
loid PET based on binary reading (negative or positive). 
With binary reading, the visual evaluation of PiB images 
can result in equivocal ratings [11]. With trinary reading, 
in which the judgement criterion of “equivocal” is defined, 
equivocal PET images may represent subtle accumulation 
in the earliest phase in the progression of amyloid accumu-
lation that is likely to be overlooked by image interpreta-
tion using binary reading [12]. In J-ADNI, amyloid-β1-42 
in cerebrospinal fluid samples (CSF-Ab42) was measured at 
baseline. Low CSF-Ab42 is considered the best biomarker 
that represents a pathologic state that is associated with 
amyloid plaque formation [1]. The objectives of the pre-
sent study were to investigate (1) whether trinary visual 
interpretation of amyloid PET imaging (negative/equivocal/
positive) reflects quantitative amyloid measurements and the 
time course of PiB amyloid accumulation, and (2) whether 
visually equivocal scans represent an early stage of the AD 
continuum [13] in terms of an intermediate state of quan-
titative amyloid measurements and time course of amyloid 
accumulation, as well as CSF-Ab42.
Methods
Data used in preparation of this article were obtained from 
the J-ADNI database deposited in the National Bioscience 
Database Center (NBDC) Human Database, Japan (Research 
ID: hum0043.v1, 2016). The J-ADNI is a multicenter, longi-
tudinal observational study of AD launched in 2007 as a pub-
lic–private partnership, led by Principal Investigator Takeshi 
Iwatsubo, MD. In J-ADNI, individuals who were cognitively 
normal (CN), those with late mild cognitive impairment [14] 
(LMCI), and those with mild Alzheimer’s type dementia [15] 
(ADD) between the ages of 60 and 84 years were diagnosed 
and enrolled using inclusion and exclusion criteria harmonized 
with the Alzheimer’s Disease Neuroimaging Initiative [16]. 
Approval for the J-ADNI study protocol (UMIN000001374) 
was obtained from the local ethics committees or institutional 
review committees at the 38 participating clinical sites. A full 
description of the J-ADNI cohort has been reported elsewhere 
[17]. The latest data used in this study were downloaded on 
October 25, 2016. This study was approved by the Ethics 
Committee of the National Center for Geriatrics and Geron-
tology (no. 925-4). The authors have no competing interests 
to declare.
From the J-ADNI database, the individuals selected for this 
study included 33 with ADD, 52 with LMCI, and 48 who 
were CN. All study participants underwent neuropsychologi-
cal assessments, PiB PET, and structural magnetic resonance 
imaging (MRI) (Fig. 1). The imaging examinations were per-
formed, as a general rule, at baseline, 12 months, 24 months 
for all clinical categories, and 36 months for CN and LMCI 
between September 2008 and September 2014. The time 
interval between neuropsychological tests and PiB PET in 
each visit was 10.3 ± 13.2 days (mean ± standard deviation 
(SD)). The time interval between MRI and PiB PET was 
14.5 ± 22.0 days (mean ± SD).
The basic characteristics of the 133 individuals stratified 
by clinical diagnoses are shown in Table 1. There were no 
significant differences in sex or ApoE ε2 or ε4 distributions 
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among the groups. The ADD group was significantly older, 
had fewer years of school education, and scored worse on 
each neuropsychological examination than the LMCI and CN 
groups. The LMCI group was significantly older and scored 
worse on each neuropsychological examination than the CN 
group. In the present study, the number of individuals who 
underwent three or more PiB PET scans was 47 (97.9%) in 
the CN group, 49 (94.2%) in the LMCI group, and 28 (84.8%) 
in the ADD group. The duration of follow-up for PiB PET 
was 2.89 ± 0.37 years in CN, 2.69 ± 0.56 years in LMCI, and 
1.79 ± 0.36 years in ADD.
The ApoE genotype was determined by direct sequenc-
ing [18]. Clinical Dementia Rating (CDR) was performed for 
assessment of the clinical status in this study. CDR has been 
commonly used to assess the severity of dementia [19].
Imaging
The 133 individuals underwent a PiB PET scan at baseline 
and additional scans every 12 months during the follow-up 
periods of 2 (ADD) or 3 years (CN and LMCI) at 11 sites 
that used a total of seven different PET scanner models by 
three vendors (2 GE Advance, 2 GE Discovery ST Elite, 20 
Shimadzu Eminence G/X, 21 Shimadzu Eminence SOPHIA 
B/L, 40 Shimadzu HEADTOME V, 36 Siemens Biograph 
16, and 12 Siemens ECAT ACCEL). Inter-site differences 
were minimized by standardizing the imaging protocol [20]. 
All PET images acquired at each PET site went through the 
J-ADNI PET quality control (QC) process [10, 20], in which 
head motion between frames was corrected before creating 
images of summed frames (sumframe images) of 50–70 min 
(300 s × 4 frames) after injection of PiB (555 ± 185 MBq). 
Correction of attenuation was processed by an additional 
6-min transmission scan with segmentation for dedicated 
PET scanners or by a computed tomography (CT) scan for 
PET/CT scanners [10, 20]. Five PiB images (four images at 
baseline, one image at the follow-up period of 12 months) 
were excluded from this study because they included severe 
movement during imaging or an excessively short imaging 
duration (Fig. 1).
Structural MRI was performed with 1.5-T MRI scanners 
using a three-dimensional sagittal magnetization-prepared 
rapid gradient-echo imaging (MPRAGE) sequence accord-
ing to a standardized protocol [18] at each PiB follow-up 
period. For the 133 individuals, a total of 5 MRI scanner 
models by three vendors were used (34 GE SIGNA EXCITE, 




The PiB PET images generated through the QC process 
above were independently interpreted visually by three 
expert raters blinded to the clinical category. Information 
Fig. 1  Diagram showing the 




CN 170, LMCI 349, AD 196
Total enrolled to J-ADNI:
n = 537
CN 154, LMCI 234, AD 149
Individuals with clinical diagnosis, 
PiB, and MRI data at baseline and
one/more follow-up visits:
n = 138
CN 50, LMCI 53, AD 35
Individuals enrolled to this study:
n = 133
CN 48, LMCI 52, AD 33
Exclusion of PiB images
1. PiB images with frame-out of cerebellum
2. PiB images reported as including
severe movement at imaging or
excessively short imaging duration
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about age, sex, and T1-weighted MRI images was provided 
to the raters. In the visual interpretation, the raters evaluated 
the regional PiB uptake for each of four cortical areas on 
each side (frontal lobe, lateral temporal lobe, lateral parietal 
lobe, and precuneus/posterior cingulate gyrus) as positive, 
equivocal, or negative regional uptake, the definitions of 
which were as follows: positive, uptake is clearly higher than 
in cerebral white matter that covers more than one gyrus 
of the cerebral cortical area; equivocal, uptake is slightly 
higher than or similar to that in cerebral white matter that 
covers more than one gyrus of the cerebral cortical area, i.e., 
radioactivity extending beyond white matter to the corti-
cal surface, or a high uptake spot limited to one gyrus; and 
negative, uptake is lower than in cerebral white matter in any 
region of the cerebral cortex. Of the total scans in J-ADNI, 
91.3% of the visual assessments were matched among the 
three raters (Cohen kappa = 0.88). After independent inter-
pretations, consensus reading was performed to determine 
the unified visual interpretation for each PET image by the 
three raters and two other experienced discussants [10]. The 
unified visual interpretation stored in the J-ADNI was used 
for this study.
Quantitative evaluation
MPRAGE MR images that were interpolated were con-
verted into images of a cubic voxel (1.2 × 1.2 × 1.2  mm3) 
using the Voxel-based Specific Regional analysis system for 
Alzheimer’s Disease (VSRAD) [21]. The sumframe images 
of PiB were coregistered to the individual MR images using 
Pmod 3.4 (https ://www.pmod.com/web/) with a combina-
tion of methods (dissimilarity function: normalized mutual 
information; interpolation of pixel values: trilinear; resa-
mpling density: 5.2 mm; minimization method: Powell’s 
method [22]). The cubic voxel MRI images were segmented 
into grey matter images using the Statistical Parametric 
Mapping software package (SPM8) (https ://www.fil.ion.ucl.
ac.uk/spm/softw are/spm8/). The coregistered PiB images 
and grey matter-segmented MR images were spatially nor-
malized in stereotactic space of the Montreal Neurologi-
cal Institute (MNI) 152 template [23] using Diffeomorphic 
Anatomical Registration using Exponentiated Lie Algebra 
(DARTEL) [24], with parameters obtained from the indi-
vidual MR images. Grey matter-mask images were made 
with binarization from the spatially normalized grey mat-
ter-segmented MR images using an in-house program. The 
normalized PiB PET images were masked with the grey 
matter-mask MR images to exclude the white matter and 
regions outside the brain. The region of interest (ROI) val-
ues were obtained from the PiB images of the grey matter 
using the Automated Anatomical Labeling Atlas [25]. All 
ROI values were transformed into SUVRs by dividing them 
by the average ROI value in the cerebellar cortex as refer-
ence, because 6-CN-PiB binding to diffuse amyloid plaques 
in the cerebellum cortex was not detectable in a pathologi-
cal study [2]. The mean cortical SUVR was obtained by 
averaging the ROI values of the frontal, parietal, and tem-
poral ROIs [26, 27].
CSF biomarkers
A total of 68 (11 ADD, 32 LMCI, 25 CN) individuals in this 
study underwent a lumbar puncture at baseline. CSF-Ab42 
in the CSF samples was assayed using the multiplex xMAP 
Luminex platform (Luminex Corp, Austin, TX) with Innoge-
netics (INNO-BIA AlzBio3; Ghent, Belgium) immunoassay 
kit-based reagent as validated previously [28] at the J-ADNI 
biomarker core at Niigata University [17].
Table 1  Demographic of the individuals
Unless otherwise indicated, data are expressed as mean (SD). The 
items other than ΔSUVR shows data at baseline
ApoE apolipoprotein E, CDR Clinical Dementia Rating-Japanese, 
CDR-SOB Clinical Dementia Rating-Japanese sum of boxes, MMSE 
Mini-Mental State Examination, ADAS Alzheimer’s Disease Assess-
ment Scale-cognitive component-Japanese version, ΔSUVR annual 
change in SUVR
* ✝Significantly different from their respective CN group
☨ Significantly different from LMCI group
**, ✝✝,☨☨p < 0.001
* ☨p < 0.05, significance levels are shown without multiple compari-
sons
a The individuals with available CSF data were 25 (52.1%) in CN, 32 
(61.5%) in LMCI, and 11 (33.3%) in ADD group
CN (n = 48) LMCI (n = 52) ADD (n = 33)
Age, years 66.8 (4.5) 71.6 (5.1)✝✝ 74.6 (6.8)**☨
Male sex, no. (%) 24 (50%) 24 (46.2%) 16 (48.5%)
Years of education 13.9 (2.3) 13.8 (2.9) 12.6 (3.3)*
ApoE ε2 + , no. (%) 4 (8.3%) 3 (5.8%) 1 (3%)
ApoE ε4 + , no. (%) 16 (33.3%) 24 (46.2%) 14 (42.4%)
CDR 0 (0) 0.5 (0) 0.6 (0.2)**☨☨
CDR-SOB 0 (0.1) 1.6 (1) ✝✝ 3.5 (1.3)**☨☨
MMSE 29.5 (0.9) 26.6 (1.8) ✝✝ 22.2 (1.6)**☨☨
ADAS 4.6 (2.7) 9.1 (4.3)✝✝ 16.6 (4.6)**☨☨
CSF-Ab42 (pg/mL)a 425 (117) 324 (138)✝ 272 (62)**
PiB visual interpretation
 Negative, No. (%) 34 (70.8%) 18 (34.6%) 3 (9.1%)
 Equivocal, No. (%) 5 (10.4%) 1 (1.9%) 2 (6.1%)
 Positive, No. (%) 9 (18.8%) 33 (63.5%) 28 (84.8%)
PiB SUVR 1.21 (0.28) 1.56 (0.43)✝✝ 1.81 (0.41)**☨
ΔSUVR (/year) 0.01 (0.03) 0.03 (0.06)✝✝ 0.02 (0.07)
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Statistical analyses
The subject’s characteristics at baseline were summarized 
by frequency and percentage for categorical variables and 
by means and SDs for continuous variables. Group com-
parisons were made by Fisher’s exact test for categorical 
variables and the t test for continuous variables. Single 
regression analyses of SUVRs at available time points for 
each participant were performed to calculate the annual 
increase in SUVRs. For reference, the upper confidence 
limit of the 97.5 percentile for the baseline SUVR in the 
amyloid-negative CN group was calculated. The mean/
SD of the SUVR at baseline and the annual change in the 
SUVR were calculated for each group corresponding to 
each visual judgment and clinical category. Statistical anal-
ysis of baseline SUVR, annual change in SUVR, and base-
line CSF-Ab42 levels were compared by one-way analysis 
of variance, followed by post-hoc comparisons using the 
Bonferroni correction. Statistical analyses were performed 
using SPSS version 25.
Results
With trinary visual interpretation of the PiB PET images, 
55 subjects were negative, eight were equivocal, and 70 
were positive. In the CN group, negative was most fre-
quent (34/48, 70.8%), whereas five participants were 
equivocal (10.4%), and nine were positive (18.8%). In the 
LMCI group, positive was most frequent (33/52, 63.5%), 
whereas 18 participants were negative (34.6%), and one 
was equivocal (1.9%). In the ADD group, positive was 
most frequent (28/33, 84.8%), whereas three participants 
were negative (9.1%), and two were equivocal (6.1%). The 
PiB SUVR was significantly different among the groups 
(CN 1.21 ± 0.28; LCMI 1.56 ± 0.43; ADD 1.81 ± 0.28). 
The SUVR change per year was significantly higher in 
the LCMI group than in the CN group, but the annual 
change of SUVR changes in the ADD group did not differ 
from those in the LMCI and CN groups. CSF-Ab42 was 
significantly higher in the CN group than in the LMCI and 
ADD groups, but no significant difference between the 
LMCI and ADD group was found (Table 1). Trinary visual 
interpretation in the CN group did not define the course 


























































































































































Fig. 2  Individual longitudinal changes in SUVR during the 3-year 
follow-up. Scatterplots show the SUVR at baseline and in the 3-year 
follow-up. The dotted line shows the SUVR threshold of 1.20 derived 
from the upper confidence limit of the 97.5 percentile for the baseline 
SUVR in the amyloid-negative CN group. Negative PiB visually amy-
loid-negative, Equivocal PiB visually equivocal, Positive PiB visually 
amyloid-positive, ΔSUVR the annual change in the SUVR
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group, zero of five subjects in the equivocal group, and one 
of nine subjects in the positive group showed worsening 
of clinical symptoms from CDR 0 to 0.5.
Figure 2 shows the time courses of SUVRs grouped by 
visual assessment and by clinical category. In the amyloid-
negative CN group, the upper confidence limit of the 97.5 
percentile for the baseline SUVR was 1.20. Most SUVRs in 
the amyloid-negative group (LMCI, ADD) remained below 
this level. In the amyloid-equivocal group, no evident dif-
ferences in the longitudinal trends of SUVR were observed 
among the CN, LMCI, and ADD groups. In the amyloid-
positive group, all individual values remained above SUVR 
1.3, indicating a clear difference in the distribution of the 
SUVR between the amyloid-positive and amyloid-negative 
groups. In the visually amyloid-positive group, the annual 
changes in the SUVR were 0.04 ± 0.04 in the CN group, 
0.04 ± 0.07 in the LMCI group, and 0.03 ± 0.07 in the ADD 
group. The SUVRs in the amyloid-positive CN group tended 
to increase over time from a lower baseline SUVR com-
pared with the LMCI and ADD groups. Conversely, no 
evident differences in the longitudinal trends of SUVR were 
observed among the LMCI and ADD groups. In the visually 
amyloid-positive group, 19 individuals showed a decreasing 
SUVR (CN n = 1, LMCI n = 8, ADD n = 10). The baseline 
SUVR in these individuals was significantly higher than the 
baseline SUVR of all visually amyloid-positive individuals 
(2.10 ± 0.33 vs 1.86 ± 0.31, p = 0.003).
Baseline SUVR, annual changes in the SUVR, and the 
baseline CSF-Ab42 level in the visual interpretation groups 
are presented as mean/SDs (Fig. 3). Comparison of groups 
stratified by visual assessment alone showed that the baseline 
SUVRs were 1.08 ± 0.06 in the negative group, 1.23 ± 0.15 
in the equivocal group, and 1.86 ± 0.31 in the positive 
group (F = 174.9, p < 0.001). The annual change in SUVR 
was − 0.00 ± 0.02 in the negative group, 0.02 ± 0.02 in 
the equivocal group, and 0.04 ± 0.07 in the positive group 
(F = 8.4, p < 0.001). The baseline CSF-Ab42 level was 
463 ± 112 pg/mL in the negative group, 383 ± 125 pg/mL in 
the equivocal group, and 264 ± 69 pg/mL in the positive group 



































































n=55 n=8 n=70 n=55 n=8 n=70 n=28 n=4 n=36
Fig. 3  Box-plots of longitudinal changes in SUVR and the baseline 
CSF-Ab42 level in the visual interpretation groups. a Box-plots show 
the baseline SUVR. b Box-plots show the annual changes in SUVR. c 
Box-plots show the baseline CSF-Ab42 level in individuals with avail-
able CSF data. The SUVR at baseline in the visually amyloid-posi-
tive group was significantly higher than that in the amyloid-negative 
group and amyloid-equivocal group (p < 0.001). The annual change 
in the SUVR in the visually amyloid-positive group was significantly 
higher than that in the amyloid-negative group (p < 0.001). The CSF-
Ab42 level at baseline in the visually amyloid-positive group was sig-
nificantly lower than that in the amyloid-negative group (p < 0.001) 
and the amyloid-equivocal group (p < 0.05). *p < 0.001, **p < 0.05, 
Negative PiB visually amyloid-negative, Equivocal PiB visually 
equivocal, Positive PiB visually amyloid-positive
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annual change in SUVR, and the CSF-Ab42 level between the 
negative and positive groups were significant (p < 0.001). The 
mean baseline SUVR, annual change in SUVR, and CSF-Ab42 
level in the amyloid-equivocal group were between those in 
the amyloid-negative and -positive groups. The differences in 
baseline SUVR and the CSF-Ab42 level between the equivo-
cal and positive groups were significant (p < 0.001, p < 0.05), 
although the difference in the annual change in SUVR was 
not significant (p = 1.00). The differences in all parameters 
were not significant between the amyloid-equivocal and amy-
loid-negative group (p = 0.29 for baseline SUVR, p = 0.87 for 
annual change of SUVR, and p = 0.33 for CSF-Ab42).
Additionally, we performed an analysis with the CN 
group to see the effect of trinary visual interpretation in 
subjects in the very early stage of the AD continuum. 
The differences in baseline SUVR, annual changes in the 
SUVR, and baseline CSF-Ab42 levels in CN individuals 
were evaluated in terms of visual interpretation (Fig. 4). 
In CN individuals, the baseline SUVRs were 1.08 ± 0.06 in 
the negative group, 1.23 ± 0.19 in the equivocal group, and 
1.70 ± 0.30 in the positive group (F = 63.4, p < 0.001). The 
annual change in SUVR was − 0.00 ± 0.02 in the negative 
group, 0.02 ± 0.02 in the equivocal group, and 0.04 ± 0.04 
in the positive group (F = 13.0, p < 0.001). The baseline 
CSF-Ab42 level was 461 ± 97 pg/mL in the negative group, 
426 ± 113 pg/mL in the equivocal group, and 261 ± 63 pg/
mL in the positive group (F = 7.3, p = 0.004). The differ-
ences in baseline SUVR, the annual change in SUVR, 
and the CSF-Ab42 level between the negative and positive 
groups were significant (p < 0.001 for baseline SUVR, 
p < 0.001 for annual change of SUVR, and p = 0.003 for 
CSF-Ab42). The differences in baseline SUVR between the 
equivocal and positive groups were significant (p < 0.001), 
although the difference in the annual change in SUVR and 
the CSF-Ab42 level was not significant (p = 0.13, p = 0.10). 
No significant differences were observed in these param-
eters between the amyloid-equivocal group and the amy-
loid-negative group (p = 0.13 for baseline SUVR, p = 0.41 
for annual change of SUVR, and p = 1.00 for CSF-Ab42). 






































































Fig. 4  Box-plots of longitudinal changes in SUVR and the baseline 
CSF-Ab42 level in CN individuals. a Box-plots show the baseline 
SUVR. b Box-plots show the annual changes in SUVR. c Box-plots 
show the baseline CSF-Ab42 of CN individuals with available CSF 
data. In CN individuals, the SUVR at baseline in the amyloid-posi-
tive group was significantly higher than that in the amyloid-negative 
group and amyloid-equivocal group (p < 0.001). The annual change 
in the SUVR in the amyloid-positive group was significantly higher 
than that in the amyloid-negative group (p < 0.001). The CSF-Ab42 
level at baseline in the amyloid-positive group was significantly 
lower than that in the amyloid-negative group (p = 0.003). *p < 0.001, 
**p = 0.003, Negative PiB visually amyloid-negative, Equivocal PiB 
visually equivocal, Positive PiB visually amyloid-positive
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had a tendency to distribute between the amyloid-negative 
and amyloid-positive groups.
Discussion
In recent years, the detection of the earliest accumula-
tion of amyloid has received great emphasis, because it 
is necessary to accurately determine the progression of 
amyloid pathology [29], and develop amyloid-targeted 
therapeutic protocols [30]. When determining the cutoff 
value of the mean cortical SUVR for positive and negative 
judgement, performing a receiver operating characteristic 
using the clinical diagnosis as standard of truth is com-
mon [31, 32]. However, cutoff levels determined in this 
manner do not detect the earliest accumulation of amyloid, 
because the SUVR is the average of cortical uptake and 
may not reflect localized and/or weak but abnormal uptake 
[9]. Attempts have been made to determine the cortical 
mean accumulation that corresponds to a subtler accumu-
lation [29, 33, 34]. Visual reading may be more sensitive 
to focal and asymmetric increases in PiB than semiquan-
titative method, although this sensitivity could produce 
false positives [9]. Visual reading may interpret such cases 
as equivocal. In many cases, definitive visually-positive 
or -negative PET images are presented, but a few cases 
present with images that are neither positive nor negative. 
In the J-ADNI study, such PET images were defined as 
equivocal, and visual readings of PiB PET were performed 
using a trinary reading method for evaluating negative, 
equivocal, and positive scans [10]. Images visually inter-
preted as equivocal in the J-ADNI may be judged negative 
if they are interpreted visually by applying the binary read-
ing criteria in F-18 labeled amyloid tracers. In this study, 
we used the longitudinal data of CSF-Ab42 and PiB PET 
to verify whether this equivocal determination can detect 
a subtle initial accumulation of amyloid.
When the three clinical groups (ADD, LMCI, and CN) 
were combined, the baseline SUVR, annual change in the 
SUVR, and CSF-Ab42 levels were statistically compared 
among the visually amyloid-negative, visually equivocal, 
and the visually amyloid-positive groups (Fig. 3). A one-
way analysis of variance showed a significant difference in 
the mean values of the three groups. The amyloid-equivocal 
group had intermediate parameter values that were between 
the negative and positive groups. Statistical analysis of the 
CN group alone also showed the same results (Fig. 4). The 
visually amyloid-equivocal group was identified as having 
an intermediate status of amyloid pathology in terms of the 
SUVR, its annual change, and the biological indicator, CSF-
Ab42. These results suggest that individuals with visually 
equivocal scans are at higher risk of progression of amyloid 
accumulation compared to those with visually amyloid-
negative scans.
In individuals evaluated as visually amyloid-negative, 
their SUVRs remained within the 97.5 percentile of the 
baseline SUVR over time. This finding was observed 
regardless of the clinical categories of CN, LMCI, and 
ADD (Fig. 2). Barring a few exceptions, individuals with 
an amyloid-negative image showed no trend towards a grad-
ual increase in the SUVR. In the amyloid-negative group, 
very few individuals showed an upward trend in the SUVR. 
Similar cases have been found in other longitudinal cohorts 
[4, 35], suggesting that they may represent the very early 
stage when amyloid accumulation has turned upward. On 
the other hand, individuals with a visually amyloid-positive 
image showed a time course with an SUVR of 1.3 or higher. 
The SUVR in the visually amyloid-positive group showed a 
gradual increase with a few exceptions. This was consistent 
with previous studies that reported [4–7, 36, 37] that when a 
cut-off value of SUVR or distribution volume ratio dividing 
low and high accumulation was used, the high accumulation 
group showed a gradual increasing tendency above the cut-
off value, and the low accumulation group did not show an 
increasing tendency under the cut-off value. These findings 
suggest that the risk of progression of amyloid accumulation 
is low in the visually-negative group, whereas the visually-
positive group is at an increased risk as well as SUVRs.
In the present study, some individuals with relatively 
high SUVR in the visually amyloid-positive group showed 
decreased SUVR during follow-up. Similar reports have 
been made in the past, but the reasons are unclear [4, 36, 38]. 
In general, amyloid deposition may demonstrate a sigmoidal 
increase and reach a plateau around maximum accumulation 
[4, 38]. This finding means that the rate of amyloid deposi-
tion slows after reaching the peak speed in the progression 
of amyloid pathology. PiB accumulation may decrease for 
the following reasons: (1) slowing of the accumulation rate 
(2) partial volume effect due to progressive brain atrophy (3) 
statistical errors, and (4) unknown pathological changes that 
reduce amyloid plaques. The contribution of errors in cal-
culating SUVR cannot be excluded. However, considering 
that the test–retest variability of SUVR is about 3–7%, and 
the decrease was observed at consecutive time intervals [39], 
the cause of the continuous decrease cannot be attributed to 
only the reproducibility of SUVR.
SUVRs can vary depending on the method of calculation, 
such as the ROI setting, and they are problematic when com-
parisons are made between studies. The SUVR of 1.2–1.3, 
which was considered a cutoff corresponding to visual inter-
pretation of negative/positive in the present study (Fig. 3), 
was lower than the value of 1.5 reported by Yamane et al. 
[10]. SUVRs were calculated using an in-house method [26, 
27], because the SUVRs used by Yamane et al. are not avail-
able in the NBDC database. The disagreement was thought 
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to be caused by the difference in the setting of ROIs, such 
as using the Automated Anatomical Labeling [25] atlas and 
excluding areas other than cortices segmented with MRI.
ApoE ε4 is considered to be an important risk factor for 
amyloid deposition [40]. As shown in the Online resource 
most individuals in the amyloid-negative group did not carry 
ApoE ε4. In the amyloid-negative CN group, the annual 
change in the SUVR was significantly higher in ApoE ε4 
carriers [0.01 ± 0.02 (mean ± SD)] than in non-carriers 
(− 0.01 ± 0.02) (p = 0.02). ApoE ε4 carriers were deemed 
to represent an increasing SUVR, even though ApoE ε4 car-
riers were visually amyloid-negative. On the other hand, pre-
senting firm findings in other groups was difficult, because 
the sample size was insufficient for statistical investigation 
of the effect of ApoE ε4. For reference, a statistical summary 
of ε4 carriers and non-carriers in each group is provided 
(Online resource).
PiB PET visual interpretation is inevitably affected by 
each rater’s experience and potential personal bias. In the 
overall individuals in the J-ADNI study, agreement in the 
trinary visual interpretation (negative/equivocal/positive) 
was 91.3% among the three raters (Cohen kappa = 0.88) 
[10]. The interpretation of equivocal cases was not indis-
tinct from the others, as the agreement rate and Cohen 
kappa of binary visual interpretation (negative/positive) 
did not differ from the trinary interpretation (92.3% and 
0.89%, respectively).
Whether the results obtained with PiB PET can be 
applied to F-18-labeled amyloid PET is unclear, because 
PiB has a different contrast from F-18 amyloid tracers.
Our study has several limitations. First, the sample 
size was relatively small, and the follow-up duration was 
relatively short for observing changes in clinical status, 
especially for tracking CN individuals, although we imple-
mented all available data from the J-ADNI study. Further 
validation in other cohort studies is needed.
Second, the results were potentially influenced by 
several methodological factors. We did not apply partial 
volume correction (PVC) in this study. This was because 
Villemagne et al., in their longitudinal PiB-PET study [4], 
employed data without PVC for the main results, as they 
found that PVC induced considerable noise and increased 
variances in their data. However, SUVRs in the current 
study could be affected by brain atrophy. Also, computa-
tion of SUVRs can introduce errors, and the methodol-
ogy itself as well as within-subject variability in his/her 
general condition such as brain circulation can introduce 
errors. Engler et al. studied the test–retest variability of 
PiB-PET SUVRs in four subjects within 20 days, and 
found variances of 3–7% [39]. Thus, the large variances 
found in the current study need to be interpreted while 
considering the influence of these factors.
Conclusion
Trinary visual interpretation (negative/equivocal/positive) of 
amyloid PET imaging reflects quantitative amyloid measure-
ments evaluated by PET and the CSF amyloid test as well as 
the amyloid accumulation over time evaluated by PET over 
the 3 years. Subjects in the early stage of the AD continuum 
could be identified when they showed an equivocal scan, 
because they showed intermediate quantitative amyloid PET 
and CSF measurements as well as the amyloid accumulation 
over time.
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